Neuphoria Provides First Quarter 2025 Business Updates
Provided By GlobeNewswire
Last update: May 20, 2025
BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business updates for the First Quarter of 2025.
Read more at globenewswire.com4.22
-0.16 (-3.65%)
Find more stocks in the Stock Screener
NEUP Latest News and Analysis
